Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12. Juni 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear...
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
11. Juni 2024 17:47 ET
|
Ultragenyx Pharmaceutical Inc.
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment...
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
04. Juni 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
30. Mai 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today...
Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
28. Mai 2024 02:00 ET
|
Ultragenyx Pharmaceutical Inc.
Evkeeza is een eerste klasse geneesmiddel dat wordt aanbevolen voor vergoeding door het Nederlands Agentschap voor Gezondheidstechnologie voor de behandeling van HoFH bij patiënten ≥ 5 jaar oud ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17. Mai 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
07. Mai 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
02. Mai 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million,...
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
30. April 2024 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to...
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
30. April 2024 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies...